Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Ocrelizumab in Multiple Sclerosis
NCT05269004Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- May 2022
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events up to 44 months. Started May 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05269004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05269004.